ClinicalTrials.gg
CompletedNCT06495944Updated Jul 1, 2025

Impact of Itraconazole on the Pharmacokinetics and Safety of Dazucorilant in Healthy, Adult Participants

A Phase 1 interventional study of Dazucorilant and Itraconazole in Healthy Adults, sponsored by Corcept Therapeutics. Completed at 1 site in United States. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-07-01.

Sponsored by Corcept Therapeutics · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Aug 2024, 2 years 3 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
21
Allocation
Not applicable
Ages
18 Years to 60 Years
Sex
All
01

Study summary

This study aims to answer how repeat doses of itraconazole impact the pharmacokinetics, safety, and tolerability of single doses of dazucorilant in healthy adults.

Participants in this study will complete screening assessments within 28 days before the first dose of study drug. Those participants who can participate will be admitted to the clinical pharmacology center (CPC) and complete pretreatment tests. Those participants will stay at the CPC for the duration of the study. On Days 1 and 8, each participant will receive a single oral dose of dazucorilant 300 mg, after eating. On Days 5-11, all participants will receive once daily, oral doses of itraconazole 200 mg, after eating. Blood and safety assessments will continue for 96-hours after dosing on Day 1 and Day 8. Participants will leave the CPC following completion of all procedures on Day 12.

Participants will return to the CPC for a final visit 7 (±1) days after their final dose of study medication.

02

Conditions studied

  • Healthy Adults
03

In context

Lead sponsor

Corcept Therapeutics is the lead sponsor of 73 studies on the registry; 3 are open to participants now.

Of its 32 completed or terminated interventional studies of FDA-regulated products, 9 (28%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Be capable of and willing to comply with study restrictions and procedures
  • Female participants must be non-nursing, have a negative pregnancy test result at screening and Day -1, and be surgically sterile for at least 90 days prior to screening or
  • Male participants with female partners of child bearing potential must agree to use 2 acceptable forms of for the duration of the study and for 90 days following the last administration of the drug; all male participants must refrain from donating sperm for this same period
  • Be considered healthy by the Investigator, based on participant's reported medical history, full physical examination, clinical laboratory tests, 12-lead (ECG) and vital signs
  • Have normal renal function as determined by Investigator
  • Have a (BMI) of 18.0 to 30.0 kg/m\^2 inclusive and body weight >50.0 kg at screening
  • Have no relevant dietary restrictions
  • Be willing to comply with COVID-19 policy

Exclusion criteria

Exclusion Criteria:

  • history of gastrointestinal, cardiovascular, musculoskeletal, endocrine, hematologic, renal, hepatic, bronchopulmonary, psychiatric, neurologic, immunologic or lipid metabolism disorders, or drug as determined by the Investigator
  • Known or suspected
  • History of pancreatitis or gall stones
  • History of unexplained syncope, symptomatic hypotension, or hypoglycemia
  • Personal or family history of long syndrome; QTcF >450 ms
  • History of chronic diarrhea, malabsorption, unexplained weight loss, food allergies or intolerance
  • Gastrointestinal, liver, kidney disease, or other diseases known to interfere with drug absorption, distribution, metabolism, or excretion within 3 months prior to the screening and during the screening period
  • Hypersensitivity to dazucorilant or itraconazole or any components of either formulation
  • Poor venous access
  • Positive blood screen for infection with (HIV), , or
  • Donated or lost ≥500 mL of blood in the previous 60 days
  • Plasma donation within 30 days prior to the 1st dose of study medication
  • Taken an drug or participated in a clinical trial within 90 days (or 5 half-lives), whichever is longer, prior to the 1st dose of study medication
  • Used prescription or over-the-counter (OTC) medication (other than ≤1 g/day acetaminophen), antacids, vitamins or herbal remedies or supplements, within 2 weeks or 5 half-lives before first study drug administration, whichever is longer
  • Used food or drugs that are inducers of /5 and/or P-glycoprotein inducers within 30 days prior to the first dose of study medication
  • Consumption of grapefruit, pomelo, or Seville oranges or their juices or jams, from 30 days prior to Day -1
  • Hospital admission or major surgery within 6 months prior to screening or a preplanned hospital admission during study participation
  • A history of prescription drug abuse or illicit drug use within 12 months prior to screening
  • Use of cannabis or cannabidiol (CBD) containing products within 30 days prior to study drug administration on Day 1
  • A history of alcohol abuse according to medical history within 2 years prior to screening
  • Use of tobacco- or nicotine-containing products or participants unwilling/unable to stop nicotine intake from 6 months prior to screening until the end of the study
  • A positive screen for alcohol, drugs of abuse, or cotinine at screening or Day -1
  • An unwillingness or inability to comply with food and beverage restrictions during study participation
  • Investigational site staff members directly involved in the conduct of the study and their family members; site staff members otherwise supervised by the Investigator or Corcept Therapeutics Incorporated employees directly involved in the conduct of the study
  • Any condition or finding that in the Investigator's opinion would put the participant or study conduct at risk if the participant were to participate in the study
  • Unable to complete this study for other reasons or the Investigator believes that he or she should be excluded
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
21 participants (actual)

Study arms

  • Experimental
    Dazucorilant (300 mg) and itraconazole (200 mg)

    On Days 1 and 8, each participant will receive a single oral dose of dazucorilant 300 mg, in a fed state. On Days 5-11, all participants will be administered once daily, oral doses of itraconazole 200 mg, in a fed state.

    Drug: Dazucorilant · Drug: Itraconazole

Interventions

  • 75 mg soft gelatin capsules formulation for oral administration

    Also known as: CORT113176

  • 100 mg capsules for oral administration

06

What researchers measure

Primary outcomes

  1. Maximum observed plasma concentration (Cmax) of dazucorilant

    Time frame: Predose and at serial timepoints up to 96 hours after dazucorilant dosing on Days 1 and 8

  2. Area under the concentration-time curve from time 0 to the last measurable concentration (AUClast) of plasma dazucorilant

    Time frame: Predose and at serial timepoints up to 96 hours after dazucorilant dosing on Days 1 and 8

  3. Area under the concentration-time curve from time 0 extrapolated to infinity (AUCinf) of plasma dazucorilant

    Time frame: Predose and at serial timepoints up to 96 hours after dazucorilant dosing on Days 1 and 8

Secondary outcomes

  1. Number of Participants with 1 or More Adverse Events

    Time frame: Up to Day 18

  2. Number of Participants with 1 or More Clinically Significant Abnormal ECG Result

    Time frame: Up to Day 18

  3. Number of Participants with 1 or More Clinically Significant Abnormal Vital Signs

    Time frame: Up to Day 18

  4. Number of Participants with 1 or More Clinically Significant Abnormal Physical Examination Finding

    Time frame: Up to Day 18

  5. Number of Participants with 1 or More Clinically Significant Abnormal Clinical Laboratory Test Result

    Time frame: Up to Day 18

07

Study locations

1 site
  • Site 01
    Baltimore, Maryland 21201, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2024 to primary completion in Aug 2024, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 3, 2024
First posted
Jul 11, 2024
StartActual
May 31, 2024
Primary completionActual
Aug 2, 2024
CompletionActual
Aug 2, 2024
Last update
Jul 1, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 1, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06495944
Responsible party
Sponsor
First posted
Jul 11, 2024
Start date
May 31, 2024
Primary completion
Aug 2, 2024
Completion
Aug 2, 2024
Last update
Jul 1, 2025

Study contacts

Joseph Custodio, PhD
study director · Corcept Therapeutics

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: CORT113176

Start the discussion